899 related articles for article (PubMed ID: 18455473)
21. Analysis of Epstein-Barr viral DNA load, EBV-LMP2 specific cytotoxic T-lymphocytes and levels of CD4+CD25+ T cells in patients with nasopharyngeal carcinomas positive for IgA antibody to EBV viral capsid antigen.
Mo WN; Tang AZ; Zhou L; Huang GW; Wang Z; Zeng Y
Chin Med J (Engl); 2009 May; 122(10):1173-8. PubMed ID: 19493466
[TBL] [Abstract][Full Text] [Related]
22. Nasopharyngeal carcinoma: the diagnostic value of the antibody-dependent, cellular cytotoxicity test and of EBV serology.
Faggioni A; Corradini C; Venanzoni M; Cardi G; Bevere F; Barile G; Zompetta C; Frati L
J Exp Pathol; 1987; 3(4):471-7. PubMed ID: 2842480
[TBL] [Abstract][Full Text] [Related]
23. Prognostic implication of pretreatment titer of serum immunoglobulin A against Epstein-Barr virus capsid antigen in nasopharyngeal carcinoma patients in Sihui, Guangdong.
Ling W; Cao SM; Huang QH; Li YH; Deng MQ
Ai Zheng; 2009 Jan; 28(1):57-9. PubMed ID: 19448418
[TBL] [Abstract][Full Text] [Related]
24. Sensitivity and specificity of Epstein-Barr virus IGA titer in the diagnosis of nasopharyngeal carcinoma: a three-year institutional review.
Tsang RK; Vlantis AC; Ho RW; Tam JS; To KF; van Hasselt CA
Head Neck; 2004 Jul; 26(7):598-602. PubMed ID: 15229902
[TBL] [Abstract][Full Text] [Related]
25. [Evaluation of immunoblot-based assay for detecting Epstein-Barr virus viral capsid antibodies].
Altuğlu I; Aksoy A; Zeytinoğlu A; Orman M
Mikrobiyol Bul; 2010 Apr; 44(2):231-6. PubMed ID: 20549957
[TBL] [Abstract][Full Text] [Related]
26. Comparison of Epstein-Barr Virus Serological Tools for the Screening and Risk Assessment of Nasopharyngeal Carcinoma: a Large Population-based Study.
Guo J; Cui Z; Zheng Y; Li X; Chen Y
Pathol Oncol Res; 2020 Oct; 26(4):2185-2190. PubMed ID: 32222897
[TBL] [Abstract][Full Text] [Related]
27. [Significance of cell-free Epstein-Barr virus DNA in monitoring prognosis of nasopharyngeal carcinoma].
Cao SM; Min HQ; Gao JS; Hong MH; Xiao XB; Zhang CQ; Liu XD; Zhang AL; Guo X
Ai Zheng; 2003 Mar; 22(3):302-6. PubMed ID: 12654192
[TBL] [Abstract][Full Text] [Related]
28. Epstein-Barr virus (EBV) serology for predicting distant metastases in a white juvenile patient with nasopharyngeal carcinoma and no clinical response to EBV lytic induction therapy.
Stevens SJ; Zwaan CM; Verkuijlen SA; Middeldorp JM
Head Neck; 2006 Nov; 28(11):1040-5. PubMed ID: 16933315
[TBL] [Abstract][Full Text] [Related]
29. Serological diagnosis of nasopharyngeal carcinoma by enzyme linked immunosorbent assay: optimization, standardization and diagnostic criteria.
Ng MH; Chen HL; Luo RX; Chan KH; Woo PC; Sham JS; Huang J; Seto WH; Smith P; Griffin BE
Chin Med J (Engl); 1998 Jun; 111(6):531-6. PubMed ID: 11245074
[TBL] [Abstract][Full Text] [Related]
30. Comparison of the prognostic impact of serum anti-EBV antibody and plasma EBV DNA assays in nasopharyngeal carcinoma.
Twu CW; Wang WY; Liang WM; Jan JS; Jiang RS; Chao J; Jin YT; Lin JC
Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):130-7. PubMed ID: 16979842
[TBL] [Abstract][Full Text] [Related]
31. Epstein-Barr virus serological markers for nasopharyngeal carcinoma in Thailand.
Puthavathana P; Sutthent R; Vitavasiri A; Wasi C; Chantarakul N; Thongcharoen P
Southeast Asian J Trop Med Public Health; 1991 Sep; 22(3):326-31. PubMed ID: 1818381
[TBL] [Abstract][Full Text] [Related]
32. Significance of plasma IgA and IgG antibodies to Epstein-Barr virus early and viral capsid antigens in Thai nasopharyngeal carcinoma.
Tiwawech D; Srivatanakul P; Karaluk A; Ishida T
Asian Pac J Cancer Prev; 2003; 4(2):113-8. PubMed ID: 12875623
[TBL] [Abstract][Full Text] [Related]
33. IgA antibodies against the Epstein-Barr nuclear antigen1 as a valuable biomarker for the diagnosis of nasopharyngeal carcinoma in Tunisian patients.
Ayadi W; Karray-Hakim H; Feki L; Khabir A; Boudawara T; Ghorbel A; Daoud J; Frikha M; Hammami A
J Med Virol; 2009 Aug; 81(8):1412-21. PubMed ID: 19551836
[TBL] [Abstract][Full Text] [Related]
34. Two-step Epstein-Barr virus immunoglobulin A enzyme-linked immunosorbent assay system for serological screening and confirmation of nasopharyngeal carcinoma.
Paramita DK; Fachiroh J; Haryana SM; Middeldorp JM
Clin Vaccine Immunol; 2009 May; 16(5):706-11. PubMed ID: 19321695
[TBL] [Abstract][Full Text] [Related]
35. Antibodies to Epstein-Barr virus in nasopharyngeal carcinoma, tonsillar carcinoma and control groups.
Oberender H; Nowak R; Donner A; Kunkel M; Gärtner L; Scholtz HJ
Acta Virol; 1983 May; 27(3):277-81. PubMed ID: 6138990
[TBL] [Abstract][Full Text] [Related]
36. Detection and analysis of anti-latent membrane protein 2A antibodies in the sera of patients with Epstein-Barr virus associated malignancies.
Chen Y; Yao K; Sun H; Qing J; Peng GY
Chin Med J (Engl); 2005 May; 118(9):725-30. PubMed ID: 15899133
[TBL] [Abstract][Full Text] [Related]
37. [Assay of Epstein-Barr virus in nasopharyngeal tissues and serum of patients with nasopharyngeal carcinoma].
Li XM; Yang CZ; Chen PJ; Su ZL; Song Y
Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2000 Sep; 14(9):400-1. PubMed ID: 12563909
[TBL] [Abstract][Full Text] [Related]
38. Anti-Epstein-Barr virus antibodies in Beijing during 2013-2017: What we have found in the different patients.
Cui J; Yan W; Xu S; Wang Q; Zhang W; Liu W; Ni A
PLoS One; 2018; 13(3):e0193171. PubMed ID: 29494658
[TBL] [Abstract][Full Text] [Related]
39. Combination of Epstein-Barr virus scaffold (BdRF1/VCA-p40) and small capsid protein (BFRF3/VCA-p18) into a single molecule for improved serodiagnosis of acute and malignant EBV-driven disease.
Fachiroh J; Stevens SJ; Haryana SM; Middeldorp JM
J Virol Methods; 2010 Oct; 169(1):79-86. PubMed ID: 20621126
[TBL] [Abstract][Full Text] [Related]
40. Serologic diagnosis of nasopharyngeal carcinoma. A double-blind study of four EB virus antibodies with evaluation by sequential discrimination.
Cai WM; Li YW; Wu B; Liu YY; Hu YH; Gu XZ; Liu HY; Wang GD
Int J Radiat Oncol Biol Phys; 1983 Dec; 9(12):1763-8. PubMed ID: 6319338
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
